FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205366953> ?p ?o ?g. }

• W4205366953 abstract "<sec> <title>BACKGROUND</title> Background: Cladribine tablets (marketed as Mavenclad®) is a new oral therapy, which has recently been listed on the pharmaceuticals benefit scheme (PBS) in Australia for treatment of relapsing MS. The current dosing schedule is for 2 courses given a year apart, which has been shown to be effective for treatment of MS up to 4 years in 75% of patients (based on annualised relapse rate). However, re-initiation of therapy after year 4 has not been studied. </sec> <sec> <title>OBJECTIVE</title> Objective: The Objective of this study is to </sec> <sec> <title>METHODS</title> Methods: This will be a multicentre, 6-year, phase IV, low interventional observational study that incorporates clinical, haematological, biochemical, epigenetic, and radiological and cognitive biomarkers of disease. Subjects considered for treatment with cladribine as part of their routine clinical care, will be consented to take part in the study. They will be monitored at regular intervals during the initial course of medication administration in year 1 and year 2. After year 3, patients will have the option for re-dosing, if clinically indicated or to switch to another disease modifying therapy. Throughout the duration of the study, we will assess blood based biomarkers including lymphocyte subsets, serum neurofilament light chain, DNA methylation and RNA analysis as well as MRI findings (brain volume/ lesion load) and cognitive performance. </sec> <sec> <title>RESULTS</title> Results: This study has been approved by the Hunter New England Local Health District Human Research Ethics Committee. Recruitment Started in Mach 2019. </sec> <sec> <title>CONCLUSIONS</title> Conclusions: This will be the first long-term efficacy trial of cladribine which offers re-initiation of therapy in the 3rd year, based on disease activity, after the initial two courses. We expect this study will indicate if any of the assessed biomarkers can be used to predict treatment efficacy or the need for future re-initiation of cladribine in MS patients. </sec> <sec> <title>CLINICALTRIAL</title> ANZCTR 376926 </sec>" @default.
• W4205366953 created "2022-01-26" @default.
• W4205366953 creator A5014375641 @default.
• W4205366953 creator A5017852596 @default.
• W4205366953 creator A5022332929 @default.
• W4205366953 creator A5025814190 @default.
• W4205366953 creator A5026073997 @default.
• W4205366953 creator A5028230236 @default.
• W4205366953 creator A5036431497 @default.
• W4205366953 creator A5058252357 @default.
• W4205366953 creator A5059129245 @default.
• W4205366953 creator A5060950347 @default.
• W4205366953 creator A5067070663 @default.
• W4205366953 creator A5080284535 @default.
• W4205366953 creator A5083946982 @default.
• W4205366953 date "2020-10-12" @default.
• W4205366953 modified "2023-09-29" @default.
• W4205366953 title "Cladribine: a multicentre, LOng-term efficacy Biomarker Australian Study (CLOBAS). A six- Otherwise we list them as CLOBAS investigators year, real-world study of multiple sclerosis patients (Preprint)" @default.
• W4205366953 doi "https://doi.org/10.2196/preprints.24969" @default.
• W4205366953 hasPublicationYear "2020" @default.
• W4205366953 type Work @default.
• W4205366953 citedByCount "0" @default.
• W4205366953 crossrefType "posted-content" @default.
• W4205366953 hasAuthorship W4205366953A5014375641 @default.
• W4205366953 hasAuthorship W4205366953A5017852596 @default.
• W4205366953 hasAuthorship W4205366953A5022332929 @default.
• W4205366953 hasAuthorship W4205366953A5025814190 @default.
• W4205366953 hasAuthorship W4205366953A5026073997 @default.
• W4205366953 hasAuthorship W4205366953A5028230236 @default.
• W4205366953 hasAuthorship W4205366953A5036431497 @default.
• W4205366953 hasAuthorship W4205366953A5058252357 @default.
• W4205366953 hasAuthorship W4205366953A5059129245 @default.
• W4205366953 hasAuthorship W4205366953A5060950347 @default.
• W4205366953 hasAuthorship W4205366953A5067070663 @default.
• W4205366953 hasAuthorship W4205366953A5080284535 @default.
• W4205366953 hasAuthorship W4205366953A5083946982 @default.
• W4205366953 hasConcept C118552586 @default.
• W4205366953 hasConcept C126322002 @default.
• W4205366953 hasConcept C143998085 @default.
• W4205366953 hasConcept C187212893 @default.
• W4205366953 hasConcept C23131810 @default.
• W4205366953 hasConcept C2777288759 @default.
• W4205366953 hasConcept C2779200787 @default.
• W4205366953 hasConcept C2780640218 @default.
• W4205366953 hasConcept C535046627 @default.
• W4205366953 hasConcept C71924100 @default.
• W4205366953 hasConceptScore W4205366953C118552586 @default.
• W4205366953 hasConceptScore W4205366953C126322002 @default.
• W4205366953 hasConceptScore W4205366953C143998085 @default.
• W4205366953 hasConceptScore W4205366953C187212893 @default.
• W4205366953 hasConceptScore W4205366953C23131810 @default.
• W4205366953 hasConceptScore W4205366953C2777288759 @default.
• W4205366953 hasConceptScore W4205366953C2779200787 @default.
• W4205366953 hasConceptScore W4205366953C2780640218 @default.
• W4205366953 hasConceptScore W4205366953C535046627 @default.
• W4205366953 hasConceptScore W4205366953C71924100 @default.
• W4205366953 hasLocation W42053669531 @default.
• W4205366953 hasOpenAccess W4205366953 @default.
• W4205366953 hasPrimaryLocation W42053669531 @default.
• W4205366953 hasRelatedWork W11845736 @default.
• W4205366953 hasRelatedWork W13479124 @default.
• W4205366953 hasRelatedWork W17271954 @default.
• W4205366953 hasRelatedWork W7472738 @default.
• W4205366953 hasRelatedWork W8843616 @default.
• W4205366953 hasRelatedWork W9199247 @default.
• W4205366953 hasRelatedWork W9511308 @default.
• W4205366953 hasRelatedWork W9635424 @default.
• W4205366953 hasRelatedWork W9657389 @default.
• W4205366953 hasRelatedWork W16747851 @default.
• W4205366953 isParatext "false" @default.
• W4205366953 isRetracted "false" @default.
• W4205366953 workType "article" @default.